Head-To-Head Contrast: MannKind (NASDAQ:MNKD) and Virax Biolabs Group (NASDAQ:VRAX)

Virax Biolabs Group (NASDAQ:VRAX) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Institutional & Insider Ownership

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by insiders. Comparatively, 3.0% of MannKind shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Virax Biolabs Group has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Comparatively, MannKind has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Virax Biolabs Group and MannKind, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1	0	1	0	2.00
MannKind	0	2	7	1	2.90

Virax Biolabs Group presently has a consensus price target of $3.00, suggesting a potential upside of 376.49%. MannKind has a consensus price target of $10.06, suggesting a potential upside of 77.16%. Given Virax Biolabs Group’s higher possible upside, equities research analysts plainly believe Virax Biolabs Group is more favorable than MannKind.

Profitability

This table compares Virax Biolabs Group and MannKind’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
MannKind	9.32%	-49.33%	6.84%

Valuation & Earnings

This table compares Virax Biolabs Group and MannKind”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10,000.00	273.25	-$6.06 million	N/A	N/A
MannKind	$285.50 million	6.11	$27.59 million	$0.10	56.80

MannKind has higher revenue and earnings than Virax Biolabs Group.

Summary

MannKind beats Virax Biolabs Group on 8 of the 13 factors compared between the two stocks.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.